Review



procedure proc loess with smoothing factor 0.25  (SAS institute)


Bioz Verified Symbol SAS institute is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    SAS institute procedure proc loess with smoothing factor 0.25
    Mean <t>GIR</t> profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population
    Procedure Proc Loess With Smoothing Factor 0.25, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/procedure+proc+loess+with+smoothing+factor+0%2E25/pmc09543887-148-11-13?v=SAS+institute
    Average 90 stars, based on 1 article reviews
    procedure proc loess with smoothing factor 0.25 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study"

    Article Title: Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study

    Journal: Diabetes, Obesity & Metabolism

    doi: 10.1111/dom.14768

    Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population
    Figure Legend Snippet: Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population

    Techniques Used: Drug discovery



    Similar Products

    procedure proc loess with smoothing factor 0.25  (SAS institute)
    90
    SAS institute procedure proc loess with smoothing factor 0.25
    Mean <t>GIR</t> profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population
    Procedure Proc Loess With Smoothing Factor 0.25, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/procedure+proc+loess+with+smoothing+factor+0%2E25/pmc09543887-148-11-13?v=SAS+institute
    Average 90 stars, based on 1 article reviews
    procedure proc loess with smoothing factor 0.25 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population

    Journal: Diabetes, Obesity & Metabolism

    Article Title: Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US ‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE ‐3 ( R ecombinant H uman IN sulin E quivalence‐3) study

    doi: 10.1111/dom.14768

    Figure Lengend Snippet: Mean GIR profiles (PPP for PD). Two profiles each receiving Biocon's Insulin‐70/30 and HUMULIN 70/30 were excluded from the PPP (n = 72) for PD based on C‐peptide exclusion rules and during the blinded database release meeting (because of extended gaps in continuous glucose monitoring), respectively. GIR, glucose infusion rates; PD, pharmacodynamics; PPP, per‐protocol population

    Article Snippet: GIR max and other time‐related PD parameters were calculated from smoothed GIR profiles (SAS procedure PROC LOESS with smoothing factor 0.25).

    Techniques: Drug discovery